Anti-IL-1 Treatment in Children Diabetic Keto-Acidosis (DKA) at Diagnosis of Type 1 Diabetes
Status:
Withdrawn
Trial end date:
2016-04-22
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled phase 2 study. Specific aim is to
evaluate feasibility and safety of anti-IL-1 (interleukin 1) treatment in the course of
standard therapy for diabetic ketoacidosis in children and its effect on intracranial
pressure.
Phase:
Phase 2
Details
Lead Sponsor:
University of Colorado, Denver
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)